Evidence map›Paper›PMID 39546165›Full record

ArticleFamilial cancer2024

The genetic landscape of Lynch syndrome in the Israeli population.

Aasem Abu Shtaya, Sofia Naftaly Nathan, Inbal Kedar, Eitan Friedman, Elizabeth Half, Gabi Lidzbarsky, Gili Reznick Levi, Ido Laish, Lior Katz, Lily Bazak and 22 more

Erratum issuedAbstract read
In one paragraph

Article in Familial cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

32 authors.

Aasem Abu ShtayaRecanati Genetics Institute, Faculty of Medicine, Rabin Medical Center - Beilinson Hospital, Tel Aviv University, Petach Tikva, Tel Aviv, Israel.
Sofia Naftaly NathanRecanati Genetics Institute, Faculty of Medicine, Rabin Medical Center - Beilinson Hospital, Tel Aviv University, Petach Tikva, Tel Aviv, Israel.
Inbal KedarRecanati Genetics Institute, Faculty of Medicine, Rabin Medical Center - Beilinson Hospital, Tel Aviv University, Petach Tikva, Tel Aviv, Israel.
Eitan FriedmanThe Meirav High Risk Clinic, Chaim Sheba Medical Center, Tel-Hashomer, and the Center for Personalized Preventive Medicine, Assuta Medical Center, Tel-Aviv, Israel.
Elizabeth HalfGI Malignancies Prevention Unit, Gastroenterology Department, Rambam Health Care Campus, Haifa, Israel.
Gabi LidzbarskyRecanati Genetics Institute, Faculty of Medicine, Rabin Medical Center - Beilinson Hospital, Tel Aviv University, Petach Tikva, Tel Aviv, Israel.
Gili Reznick LeviThe Genetics Institute, Rambam Health Care Campus, Haifa, Israel.
Ido LaishFaculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Lior KatzDepartment of Gastroenterology, Hadassah Medical Center, Jerusalem, Israel.
Lily BazakRecanati Genetics Institute, Faculty of Medicine, Rabin Medical Center - Beilinson Hospital, Tel Aviv University, Petach Tikva, Tel Aviv, Israel.
Lilach Peled PeretzGenetics Institute, Emek Medical Center, Afula, Israel.
Lina Basel SalmonRecanati Genetics Institute, Faculty of Medicine, Rabin Medical Center - Beilinson Hospital, Tel Aviv University, Petach Tikva, Tel Aviv, Israel.
Liza DouievDepartment of Genetics, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
Marina Lifshitc KalisRecanati Genetics Institute, Faculty of Medicine, Rabin Medical Center - Beilinson Hospital, Tel Aviv University, Petach Tikva, Tel Aviv, Israel.
Menachem SchechterMedical Genetics Institute, Shaare Zedek Medical Center, Jerusalem, Israel.
Michal Barzily-RokniMedical Genetics Institute, Shaare Zedek Medical Center, Jerusalem, Israel.
Nadra Nasser SamraGenetic Unit, Ziv Medical Center, Tzfat, Israel.
Naim Abu-FrehaThe Institute of Gastroenterology and Hepatology, Beer-Sheva, Israel.
Ofir Hagari-BecharRecanati Genetics Institute, Faculty of Medicine, Rabin Medical Center - Beilinson Hospital, Tel Aviv University, Petach Tikva, Tel Aviv, Israel.
Ori SegolUnit of Gastroenterology, Lady Davis Carmel Medical Center, Haifa, Israel.
Samar MattarDepartment of Surgery B, Carmel Medical Center, Haifa, Israel.
Sarit Farage BarhomRecanati Genetics Institute, Faculty of Medicine, Rabin Medical Center - Beilinson Hospital, Tel Aviv University, Petach Tikva, Tel Aviv, Israel.
Shikma MordechaiGenetic Unit, Ziv Medical Center, Tzfat, Israel.
Shiri Shkedi RafidDepartment of Genetics, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
Stavit A ShalevGenetics Institute, Emek Medical Center, Afula, Israel.
Tamar Peretz-YablonskiSharett Institute of Oncology, Hadassah Hebrew University Hospital, Jerusalem, Israel.
Zohar LeviFaculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Revital BruchimMaccabi Health Care Organization, Tel-Aviv, Israel.
Chana VinklerInstitute for Medical Genetics, Wolfson Medical Center, Holon, Israel.
Rinat Bernstein-MolhoFaculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Sari LiebermanMedical Genetics Institute, Shaare Zedek Medical Center, Jerusalem, Israel.
Yael GoldbergRecanati Genetics Institute, Faculty of Medicine, Rabin Medical Center - Beilinson Hospital, Tel Aviv University, Petach Tikva, Tel Aviv, Israel. Yaelgo43@gmail.com.ORCID 0000-0002-9855-9472

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Deciphering the spectrum and founder disease-causing variants (DCVs) in specific populations can shape and facilitate the diagnostic process of Lynch Syndrome (LS). The aim of this report was to comprehensively update on the genetic landscape of LS in the ethnically diverse Israeli-Jewish population. The cohort included 1080 carriers from 588 families; some from underrepresented, understudied Israeli ethnic groups recruited from 8 genetic institutes and high-risk clinics throughout the country. Variant classification was performed according to the American College of Medical Genetics criteria. A total of 157 DCVs were identified, 12 are reported here for the first time, and 9 reclassified. MSH2 DCVs were identified in 286 families (49%). Most DCVs (125/157, 80%) were noted in one or two families only. Sixteen DCVs, each detected in ≥ 5 families, and accounted for LS in 378/588 (64%) families. Constitutional mismatch repair deficiency (CMMRD) was diagnosed in 7 families. Twenty-five carriers (2.3%) had an additional DCV or risk alleles in another cancer susceptibility gene. In conclusion, MMR gene variant distribution in Israel is diverse. MSH2 is most commonly mutated due to founder DCVs. Though the 16 prevalent LS-associated DCVs were frequently detected in our cohort, none of them is frequently reported in the general population. These data should facilitate variant interpretation, spouse and cascade testing.

Indexed as

Colorectal Neoplasms, Hereditary NonpolyposisMutS Homolog 2 ProteinAdultAgedDNA Mismatch RepairFemaleFounder EffectGenetic Predisposition to DiseaseHumansIsraelJewsMaleMiddle AgedMSH2 protein, humanMutS Homolog 2 ProteinCMMRDDisease causing variantsFounderLynch syndromeMMR

Identifiers

PMID39546165
PMCPMC11567984

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.